Tropical diseases

Global Dengue Fever Partnering Deals and Agreements Directory 2014-2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2019
Health, Infectious diseases, Pharmaceutical, Dengue fever, Tropical diseases, Neglected diseases, Health

The "Global Dengue Fever Partnering 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dengue Fever Partnering 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Global Dengue Fever Partnering Terms and Agreements since 2014 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.
  • Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2014.
  • Global Dengue Fever Partnering Terms and Agreements since 2014 report provides the reader with the following key benefits:
    Insight into key deal terms included in contracts, where disclosed
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005522/en/

Battelle Shares Expertise on the Front Lines in the Fight Against Ebola in Africa

Retrieved on: 
Monday, March 4, 2019
Education, Technology, Other Technology, Security, Health, Travel, Other Travel, Public policy, Government, Homeland security, Other Health, Public policy, Philanthropy, Defense, Contracts, Training, Other Defense, Research, Other Science, Other Philanthropy, Consumer, Family, Science, General Health, Infectious diseases, Animal diseases, Medical specialties, Ebola, Biological weapons, Tropical diseases, Zoonoses, Animal virology, Ebola virus, Democratic Republic of the Congo Ebola virus outbreaks, West African Ebola virus epidemic

In fact, the second deadliest Ebola outbreak in history is actively ongoing in the Democratic Republic of the Congo now.

Key Points: 
  • In fact, the second deadliest Ebola outbreak in history is actively ongoing in the Democratic Republic of the Congo now.
  • Recently, two Battelle employees traveled to the Democratic Republic of the Congo for 16 days, representing the National Institute of Allergy and Infectious Diseases (NIAID).
  • Battelle staff taught Congolese researchers how to conduct serologic assays to detect immune response to Ebola virus in vaccinated and exposed individuals, as well as disease survivors.
  • When the Battelle team is in the United States, they continue to fight Ebola from the IRF at Fort Detrick in Maryland.

Global Rabies Diagnostics Markets, 2019-2025 - Key Players are Bio-Rad Laboratories, Merck, Aviva Systems Biology, and Creative Diagnostics

Retrieved on: 
Wednesday, February 27, 2019
Medicine, Health, Microbiology, Tropical diseases, RTT, Rabies, Viral encephalitis, Infection, Assay

The global rabies diagnostics market size is expected to reach USD 2.03 billion by 2025 and is projected to expand at a CAGR of 4.1% during the forecast period.

Key Points: 
  • The global rabies diagnostics market size is expected to reach USD 2.03 billion by 2025 and is projected to expand at a CAGR of 4.1% during the forecast period.
  • Development of various diagnostic assays ranging from detection of virus presence to final confirmation of infection helps launch effective disease control programs.
  • These assays aid in defining epidemiologic patterns of the disease and thereby deliver appropriate information for designing the control and eradication programs.
  • Such initiatives are projected to create growth opportunities for the rabies diagnostics market during the forecast period.

Co-Diagnostics Completes Submission of CE Mark Registration for Zika/Dengue/Chikungunya Multiplex Test

Retrieved on: 
Tuesday, February 26, 2019
Health, Biotechnology, Genetics, Infectious diseases, Research, Science, Infectious diseases, Medical specialties, Medicine, Neglected diseases, Tropical diseases, RTT, Dengue fever, Zika virus, Chikungunya, Zika fever, Aedes, Mosquito

Our multiplex test for Zika, dengue, and chikungunya was developed in direct response to market demand for an affordable, highly-specific diagnostic tool for all three diseases.

Key Points: 
  • Our multiplex test for Zika, dengue, and chikungunya was developed in direct response to market demand for an affordable, highly-specific diagnostic tool for all three diseases.
  • The three viruses are spread by the same Aedes mosquitos and have similar symptoms, including sever fever and joint pain, which has historically led to false diagnoses.
  • Our ZDC multiplex test provides patients and health care providers a low-cost solution to test for all three viruses at once, with the confidence that the test results will aid in determining the most suitable treatment for each patient.
  • The registration process is expected to be complete by early March, at which point sales of the product may commence as an IVD with the CE marking included.

Chagas Disease (American Trypanosomiasis): Global Clinical Trials Review, H2, 2018 - Top Level Data by Region, Country, Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 13, 2019
Health, Clinical trials, Infectious diseases, Pharmaceutical, Infectious diseases, Health, Medical specialties, Clinical research, Pharmaceutical industry, RTT, Neglected diseases, Tropical diseases, Chagas disease, Clinical trial, Nifurtimox

The "Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.
  • Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H2, 2018 provides an overview of Chagas Disease (American Trypanosomiasis) clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Chagas Disease.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Prior Dengue Virus Infection May Cause Severe Outcomes Following Zika Virus Infection During Pregnancy, Mount Sinai Study Shows

Retrieved on: 
Friday, February 8, 2019
Viruses, Infectious diseases, Zika virus, Medical specialties, Dengue fever, Flaviviruses, RTT, Tropical diseases, Zika fever, Dengue virus, Zika virus vaccine, 2015–16 Zika virus epidemic

This study is the first to report a possible mechanism for the enhancement of Zika virus progression during pregnancy in an animal model.

Key Points: 
  • This study is the first to report a possible mechanism for the enhancement of Zika virus progression during pregnancy in an animal model.
  • Results of the study, "Dengue virus immunity increases Zika virus-induced damage during pregnancy," were published in the February issue of Immunity, a journal published by Cell Press.
  • "Our data demonstrate that antibodies generated from a previous dengue virus infection can enhance the severity of Zika virus infection during pregnancy," said Dr. Lim.
  • Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and South Nassau Communities Hospital are ranked regionally.

NIAID-Sponsored Clinical Trial of Ebola Vaccines Begins at Cincinnati Children's

Retrieved on: 
Monday, January 28, 2019
Medical specialties, Infectious diseases, Animal diseases, Ebola, Biological weapons, Tropical diseases, Zoonoses, Vaccines, Ebola vaccine, Ebola virus, Bavarian Nordic, Julie Ledgerwood

The development of preventive vaccines for Ebola is a top global public health priority," said Paul Spearman, MD , of Cincinnati Children's and lead investigator of the trial.

Key Points: 
  • The development of preventive vaccines for Ebola is a top global public health priority," said Paul Spearman, MD , of Cincinnati Children's and lead investigator of the trial.
  • Ebola is a serious and sometimes fatal disease caused by infection with one of the Ebola viruses.
  • Laboratory evaluations of the vaccines are led by Karnail Singh, PhD , in the Division of Infectious Diseases at Cincinnati Children's.
  • The trial is studying two experimental Ebola vaccines; the ChAd3-EBO-Z vaccine and the MVA-BN-Filo vaccine.

PrimeVax Immuno-Oncology Signs Exclusive Worldwide Dengue Virus License with US Army for Cancer Treatments

Retrieved on: 
Tuesday, January 22, 2019
Dengue fever, Infectious diseases, Medical specialties, Medicine, Tropical diseases, Neglected diseases, Flaviviruses, Vaccination, Dengue vaccine, Dengue virus, Vaccine, Virus

"For decades we've developed many dengue vaccine candidates for human testing, but this is the first time that anyone will be using them for cancer treatment."

Key Points: 
  • "For decades we've developed many dengue vaccine candidates for human testing, but this is the first time that anyone will be using them for cancer treatment."
  • PrimeVax's novel therapeutic approach combines the dengue fever virus with dendritic cell therapy.
  • We are honored to have the opportunity to use the US Army's dengue virus to treat cancer patients."
  • With the US Army licensing agreement signed, PrimeVax is now working with FDA on specifics of how to administer the virus.

Ridgeback Biotherapeutics LP announces licensing of mAb114, an experimental Ebola treatment, from the National Institute of Allergy and Infectious Diseases

Retrieved on: 
Thursday, December 13, 2018
Medicine, Veterinary medicine, West African Ebola virus epidemic, Microbiology, Biological weapons, Tropical diseases, Zoonoses, Ebola virus disease, Ridgeback, Infection

The experimental treatments are being evaluated for efficacy and safety for the treatment of Ebola patients.

Key Points: 
  • The experimental treatments are being evaluated for efficacy and safety for the treatment of Ebola patients.
  • "Developing convenient and highly effective therapies is an essential tool for Ebola containment," said Wendy Holman, CEO and co-founder of Ridgeback Biotherapeutics LP.
  • Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held biotechnology company focused on orphan and infectious diseases.
  • The team at Ridgeback is dedicated to working toward finding life-saving and life changing solutions for patients and diseases that need champions.

Batavia Biosciences Partners with IAVI to Advance Development of Vaccine Against Lassa Fever

Retrieved on: 
Tuesday, December 11, 2018
Medicine, Microbiology, Tropical diseases, Health, Vaccines, Zoonoses, Lassa fever, RTT, Vesicular stomatitis virus, Lassa, International AIDS Vaccine Initiative, HIV vaccine

This process can facilitate rapid clinical development and establishment of a stockpile of an innovative new Lassa fever vaccine, which is based on the Vesicular Stomatitis Virus (VSV) vector system.

Key Points: 
  • This process can facilitate rapid clinical development and establishment of a stockpile of an innovative new Lassa fever vaccine, which is based on the Vesicular Stomatitis Virus (VSV) vector system.
  • Lassa fever, also known as Lassa hemorrhagic fever, is endemic in West Africa and can spread from person to person via contact with bodily fluids.
  • Batavia Biosciences' COO Dr Chris Yallop states: "It is an honor that IAVI has appointed Batavia Biosciences to partner in the development of such an innovative and potentially transformative vaccine production model."
  • IAVI's integrated capabilities in vaccine discovery, development, and clinical research take advantage of biopharmaceutical industry expertise to accelerate the development and testing of novel HIV vaccine candidates.